Live price temporarily unavailable.
Genelux (GNLX) is a Health Care company. Latest news and coverage below.
| FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $11.1M | $170.0K | $8.00K | $8.00K |
| Growth (year over year) | — | −98.5% | −95.3% | 0.0% |
| Operating income | −$3.01M | −$24.2M | −$31.7M | −$33.2M |
| Operating margin | −27.2% | −14214.7% | −396200.0% | −415175.0% |
| Net income | −$5.21M | −$28.3M | −$29.9M | −$32.1M |
| Net margin | −47.0% | −16645.3% | −373362.5% | −401812.5% |
| EPS (diluted) | −$0.57 | −$1.16 | −$0.95 | −$0.86 |
| Balance sheet | ||||
| Cash and equivalents | $397.0K | $9.42M | $8.56M | $5.33M |
| Total assets | $5.53M | $27.9M | $34.7M | $19.0M |
| Total liabilities | $41.3M | $8.42M | $8.44M | $7.48M |
| Shareholders' equity | −$35.8M | $19.5M | $26.3M | $11.5M |
| Cash flow | ||||
| Operating cash flow | −$3.57M | −$20.3M | −$21.2M | −$25.3M |
| Capital expenditure | $49.0K | $1.02M | $381.0K | $1.10M |
| Free cash flow | −$3.62M | −$21.3M | −$21.6M | −$26.4M |
| Q3 FY24†Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | — | — | — | — | — | — |
| Operating income | −$6.94M | — | −$7.82M | −$7.79M | −$8.19M | −$9.41M | −$9.17M | −$9.64M |
| Net income | −$6.47M | — | −$7.49M | −$7.46M | −$7.95M | −$9.25M | −$8.93M | −$9.47M |
| EPS (diluted) | −$0.19 | — | −$0.21 | −$0.20 | −$0.21 | −$0.24 | −$0.20 | −$0.21 |
| Balance sheet | ||||||||
| Cash and equivalents | $6.10M | $8.56M | $16.2M | $6.55M | $4.69M | $5.33M | $9.27M | $9.18M |
| Total assets | $40.3M | $34.7M | $39.0M | $32.2M | $25.0M | $19.0M | $32.4M | $26.2M |
| Total liabilities | $7.18M | $8.44M | $9.14M | $8.35M | $6.40M | $7.48M | $9.45M | $10.1M |
| Shareholders' equity | $33.1M | $26.3M | $29.8M | $23.9M | $18.6M | $11.5M | $22.9M | $16.1M |
| Cash flow | ||||||||
| Operating cash flow | −$5.75M | — | −$5.43M | −$7.06M | −$6.58M | −$6.20M | −$6.06M | −$6.44M |
| Capital expenditure | $27.0K | — | $30.0K | $115.0K | $517.0K | $436.0K | $921.0K | $1.53M |
| Free cash flow | −$5.78M | — | −$5.46M | −$7.17M | −$7.09M | −$6.63M | −$6.98M | −$7.98M |
From Genelux's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Genelux in our feed yet.